Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype

Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype

Objective To evaluate mepolizumab's efficacy in eosinophilic granulomatosis with polyangiitis (EGPA) with and without a vasculitic phenotype. Methods The MIRRA study (NCT02020889/GSK ID: 115921) included adults with relapsing/refractory EGPA and 4 or more weeks of stable oral glucocorticoids (O...

Full description

Bibliographic Details
Main Authors: Benjamin Terrier, David R.W. Jayne, Bernhard Hellmich, Jane H. Bentley, Jonathan Steinfeld, Steven W. Yancey, Namhee Kwon, Praveen Akuthota, Paneez Khoury, Lee Baylis, Michael E. Wechsler, the EGPA mepolizumab study team
Format: Article
Language:English
Published: Wiley 2023-07-01
Series:ACR Open Rheumatology
Online Access:https://doi.org/10.1002/acr2.11571

Internet

https://doi.org/10.1002/acr2.11571

Similar Items